Surrozen Inc.

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

Drug developers and investors left San Francisco after the recent J.P. Morgan Healthcare Conference feeling optimistic about prospects for returns on biopharmaceutical investments, certain that forthc

DURECT Corporation got disappointing Phase IIb data for its epigenetic modulator larsucosterol in alcohol-associated hepatitis (AH) on 7 November, but is hoping to convince both the US Food and Drug